Eltrombopag--a novel approach for the treatment of chronic immune thrombocytopenic purpura: review and safety considerations.

Most were able to maintain this platelet count elevation and showed a trend toward fewer bleeding events. 36 Similar promising responses were reported in a multinational phase III randomized, placebo-controlled study of 110 patients with chronic ITP. 37 The purpose of this study was to evaluate the efficacy, safety and tolerability of once daily eltrombopag (50 mg) and to explore the efficacy of a dose escalation to 75 mg.

also in 53,322 other papers